December 22, 2014 6:25 AM ET

Biotechnology

Company Overview of Nile Therapeutics, Inc

Company Overview

As of November 20, 2013, Nile Therapeutics, Inc was acquired by Capricor, Inc. Nile Therapeutics, Inc., a development stage biopharmaceutical company, develops pharmaceutical products for the treatment of cardiovascular and renal diseases. Its lead product candidate include Cenderitide, a chimeric natriuretic peptide that has completed Phase I clinical trial for the treatment of patients following admission for acutely decompensated heart failure. The company also develops CU-NP, a natriuretic peptide, which is in pre-clinical studies for the treatment of cardiovascular and renal diseases. Nile Therapeutics, Inc. was founded in 2005 and is based in San Mateo, California.

63 Bovet Road

Suite 421

San Mateo, CA 94402

United States

Founded in 2005

2 Employees

Phone:

650-918-7489

Key Executives for Nile Therapeutics, Inc

Nile Therapeutics, Inc does not have any Key Executives recorded.

Nile Therapeutics, Inc Key Developments

Nile Therapeutics, Inc will Change its Ticker to NLTXD from NLTX

Effective November 21, 2013, Nile Therapeutics, Inc will change its Pink Sheets LLC stock ticker symbol to NLTXD from NLTX.

Nile Therapeutics, Inc Proposes Amendment to Certificate of Incorporation

The Special Meeting of Stockholders of Nile Therapeutics Inc. will be held on November 12, 2013. At the meeting the shareholders proposes amendment of the company's certificate of incorporation to effect a combination (reverse split) of the company's common stock; and amendment to change the company's name from Nile Therapeutics Inc. to Capricor Therapeutics Inc.

Nile Therapeutics, Inc, Special/Extraordinary Shareholders Meeting, Nov 12, 2013

Nile Therapeutics, Inc, Special/Extraordinary Shareholders Meeting, Nov 12, 2013., at 09:00 Pacific Standard Time. Location: Bay Club, 3rd Floor Conference Room, 645 5th Street. Agenda: To authorize the amendment of the company’s certificate of incorporation to effect a combination (reverse split) of the company’s common stock at a ratio not to exceed 1:100 (the reverse stock split), and to reduce the total number of shares of common stock that are authorized to issue from 100 million to 50 million and reduce the total number of shares of preferred stock that are authorized to issue from 10 million to 5 million (the share reduction); to authorize the amendment of the company’s certificate of incorporation to change the company’s name from Nile Therapeutics, Inc. to Capricor Therapeutics, Inc.; to approve adjournments of the special meeting, if necessary, to solicit additional proxies if there are insufficient votes to approve the Charter amendment proposals; and to approve, on a nonbinding, advisory basis, the golden parachute compensation that may be paid or become payable to the company’s named executive officers in connection with the consummation of the Merger.

Similar Private Companies By Industry

Company Name Region
Cohbar, Inc. United States
Genovel Orthopedics, Inc. United States
Shamrock Structures LLC United States
Oncotide Pharmaceuticals Inc United States
Genpathway, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Nile Therapeutics, Inc, please visit www.nilethera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.